It provides truly independent analysis of the accuracy of your planned treatment and the dose delivered to the patient.
COMPASS is thus a system to increase precision and efficiency of the individual patient treatment and combines.
A (patent pending) method using a high resolution ionization chamber transmission detector and a Linac beam model allows exact fluence determination and comparison with TPS fluence.
Based on the transmission detector measurement, an advanced forward calculation algorithm subsequently reconstructs the 3D dose distribution in patient anatomy.
The 3D dose distribution is then compared with the TPS. A modern set of software tools incl. DVH allows for a side by side analysis of the two data sets either cumulative or per fraction.
COMPASS software is developed in cooperation with RaySearch Laboratories AB.
Patent Pending - FDA 510k approved
En-COMPASS your MatriXXEvolution and take IMRT verification to the patient level!
Perform treatment verification with real measurement based
COMPASS software and MatriXXEvolution : For better results.
The gantry angle sensing COMPASS 2.0 now





